Metformin potentiates the effects of paclitaxel in endometrial cancer cells through inhibition of cell proliferation and modulation of the mTOR pathway

Gynecologic Oncology

Volumn 125, Issue 2, 2012, Pages 458-469

  Hanna, Rabbie K ^a   Zhou, Chunxiao ^a   Malloy, Kimberly M ^a   Sun, Li ^b   Zhong, Yan ^c   Gehrig, Paola A ^a   Bae Jump, Victoria L ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b SHANDONG CANCER HOSPITAL AND INSTITUTE   (China)

^c Linyi Tumor Hospital   (China)

Author keywords

Endometrial cancer; Metformin; mTOR pathway; Paclitaxel

Indexed keywords

ADENYLATE KINASE; CYCLIN D1; MAMMALIAN TARGET OF RAPAMYCIN; MESSENGER RNA; METFORMIN; PACLITAXEL; PROTEIN S6; TELOMERASE REVERSE TRANSCRIPTASE;

ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; CANCER INHIBITION; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL PROLIFERATION; CONFERENCE PAPER; CONTROLLED STUDY; DOSE RESPONSE; DRUG POTENTIATION; DRUG SCREENING; ENDOMETRIUM CANCER; ENZYME PHOSPHORYLATION; FEMALE; HUMAN; HUMAN CELL; IC 50; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; CELL CYCLE; CELL GROWTH PROCESSES; CELL LINE, TUMOR; DRUG SYNERGISM; ENDOMETRIAL NEOPLASMS; FEMALE; FLOW CYTOMETRY; HUMANS; METFORMIN; PACLITAXEL; RNA, MESSENGER; SIGNAL TRANSDUCTION; TELOMERASE; TOR SERINE-THREONINE KINASES;

EID: 84858745832     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2012.01.009     Document Type: Conference Paper

References (58)

1. BergstromA, Pisani P, Tenet V,Wolk A, Adami HO. Overweight as an avoidable cause of cancer in Europe. Int J Cancer 2001;91(3):421-30 PubMed PMID: 11169969. (Pubitemid 32049639)
2. Fader AN, Arriba LN, Frasure HE, von Gruenigen VE. Endometrial cancer and obesity: epidemiology, biomarkers, prevention and survivorship. GynecolOncol 2009;114(1): 121-7 PubMed PMID: 19406460.
3. von Gruenigen VE, Gil KM, Frasure HE, Jenison EL, Hopkins MP. The impact of obesity and age on quality of life in gynecologic surgery. Am J Obstet Gynecol 2005;193(4): 1369-75 PubMed PMID: 16202728. (Pubitemid 41395106)
4. Chia VM, Newcomb PA, Trentham-Dietz A, Hampton JM. Obesity, diabetes, and other factors in relation to survival after endometrial cancer diagnosis. Int J Gynecol Cancer 2007;17(2):441-6 PubMed PMID: 17362320. (Pubitemid 46426761)
5. Cust AE, Kaaks R, Friedenreich C, Bonnet F, Laville M, Lukanova A, et al. Plasma adiponectin levels and endometrial cancer risk in pre- and postmenopausal women. J Clin Endocrinol Metab 2007;92(1):255-63 PubMed PMID: 17062769. (Pubitemid 46067541)
6. Soliman PT, Wu D, Tortolero-Luna G, Schmeler KM, Slomovitz BM, Bray MS, et al. Association between adiponectin, insulin resistance, and endometrial cancer. Cancer 2006;106(11):2376-81 PubMed PMID: 16639730. (Pubitemid 43787661)
7. Friberg E, Mantzoros CS, Wolk A. Diabetes and risk of endometrial cancer: a population-based prospective cohort study. Cancer Epidemiol Biomarkers Prev 2007;16(2):276-80 PubMed PMID: 17301260. (Pubitemid 46383346)
8. Shaw RJ, Lamia KA, Vasquez D, Koo SH, Bardeesy N, Depinho RA, et al. The kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin. Science 2005;310(5754):1642-6 PubMed PMID: 16308421. (Pubitemid 41780780)
9. Brunmair B, Staniek K, Gras F, Scharf N, Althaym A, Clara R, et al. Thiazolidinediones, like metformin, inhibit respiratory complex I: a common mechanismcontributing to their antidiabetic actions? Diabetes 2004;53(4):1052-9 PubMed PMID: 15047621. (Pubitemid 38436618)
10. Hadad SM, Fleming S, Thompson AM. Targeting AMPK: a newtherapeutic opportunity in breast cancer. Crit Rev Oncol Hematol 2008;67(1):1-7 PubMed PMID: 18343152.
11. Cantrell LA, Zhou C, Mendivil A, Malloy KM, Gehrig PA, Bae-Jump VL. Metformin is a potent inhibitor of endometrial cancer cell proliferation- implications for a novel treatment strategy. Gynecol Oncol 2010;116(1):92-8 PubMed PMID: 19822355; PubMed Central PMCID: PMC2789879.
12. GotliebWH, Saumet J, BeauchampMC, Gu J, Lau S, PollakMN, et al. In vitrometformin anti-neoplastic activity in epithelial ovarian cancer. Gynecol Oncol 2008;110(2): 246-50 PubMed PMID: 18495226.
13. Zakikhani M, Dowling R, Fantus IG, Sonenberg N, Pollak M. Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells. Cancer Res 2006;66(21): 10269-73 PubMed PMID: 17062558. (Pubitemid 44799743)
14. Zakikhani M, Dowling RJ, Sonenberg N, Pollak MN. The effects of adiponectin and metformin on prostate and colon neoplasia involve activation of AMP-activated protein kinase. Cancer Prev Res (Phila Pa) 2008;1(5):369-75 PubMed PMID: 19138981.
15. Dowling RJ, Zakikhani M, Fantus IG, Pollak M, Sonenberg N. Metformin inhibits mammalian target of rapamycin-dependent translation initiation in breast cancer cells. Cancer Res 2007;67(22):10804-12 PubMed PMID: 18006825. (Pubitemid 350145909)
16. Ben Sahra I, Laurent K, Loubat A, Giorgetti-Peraldi S, Colosetti P, Auberger P, et al. The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level. Oncogene 2008;27(25):3576-86 PubMed PMID: 18212742.
17. Buzzai M, Jones RG, Amaravadi RK, Lum JJ, DeBerardinis RJ, Zhao F, et al. Systemic treatment with the antidiabetic drug metformin selectively impairs p53-deficient tumor cell growth. Cancer Res 2007;67(14):6745-52 PubMed PMID: 17638885. (Pubitemid 47105521)
18. Hirsch HA, Iliopoulos D, Tsichlis PN, Struhl K. Metformin selectively targets cancer stem cells, and acts togetherwith chemotherapy to block tumor growth and prolong remission. Cancer Res 2009;69(19):7507-11 PubMed PMID: 19752085.
19. Evans JM, Donnelly LA, Emslie-Smith AM, Alessi DR, Morris AD. Metformin and reduced risk of cancer in diabetic patients. BMJ 2005;330(7503):1304-5 PubMed PMID: 15849206. (Pubitemid 40813563)
20. Bowker SL,Majumdar SR, Veugelers P, Johnson JA. Increased cancer-relatedmortality for patients with type 2 diabetes who use sulfonylureas or insulin. Diabetes Care 2006;29(2):254-8 PubMed PMID: 16443869. (Pubitemid 44106500)
21. Libby G, Donnelly LA, Donnan PT, Alessi DR, Morris AD, Evans JM. New users of metformin are at low risk of incident cancer: a cohort study among people with type 2 diabetes. Diabetes Care 2009;32(9):1620-5 PubMed PMID: 19564453.
22. Jiralerspong S, Palla SL, Giordano SH, Meric-Bernstam F, Liedtke C, Barnett CM, et al. Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer. J Clin Oncol 2009;27(20):3297-302 PubMed PMID: 19487376.
23. Wysocki PJ, Wierusz-Wysocka B. Obesity, hyperinsulinemia and breast cancer: novel targets and a novel role for metformin. Expert Rev Mol Diagn 2010;10(4): 509-19. PubMed PMID: 20465505.
24. Gonzalez-Angulo AM, Meric-Bernstam F. Metformin: a therapeutic opportunity in breast cancer. Clin Cancer Res 2010;16(6):1695-700. PubMed PMID: 20215559.
25. Wu C, Wangpaichitr M, Feun L, Kuo MT, Robles C, Lampidis T, et al. Overcoming cisplatin resistance by mTOR inhibitor in lung cancer. Mol Cancer 2005;4(1):25 PubMed PMID: 16033649.
26. Mondesire WH, Jian W, Zhang H, Ensor J, Hung MC, Mills GB, et al. Targeting mammalian target of rapamycin synergistically enhances chemotherapy-induced cytotoxicity in breast cancer cells. Clin Cancer Res 2004;10(20):7031-42 PubMed PMID: 15501983. (Pubitemid 39383055)
27. Mabuchi S, Altomare DA, Cheung M, Zhang L, Poulikakos PI, Hensley HH, et al. RAD001 inhibits human ovarian cancer cell proliferation, enhances cisplatin-induced apoptosis, and prolongs survival in an ovarian cancer model. Clin Cancer Res 2007;13(14):4261-70 PubMed PMID: 17634556. (Pubitemid 47105991)
28. Faried LS, Faried A, Kanuma T, Nakazato T, Tamura T, Kuwano H, et al. Inhibition of themammalian target of rapamycin (mTOR) by rapamycin increases chemosensitivity of CaSki cells to paclitaxel. Eur J Cancer 2006;42(7):934-47 PubMed PMID: 16540312.
29. Geoerger B, Kerr K, Tang CB, Fung KM, Powell B, Sutton LN, et al. Antitumor activity of the rapamycin analog CCI-779 in human primitive neuroectodermal tumor/medulloblastoma models as single agent and in combination chemotherapy. Cancer Res 2001;61(4):1527-32 PubMed PMID: 11245461. (Pubitemid 34292583)
30. Shafer A, Zhou C, Gehrig PA, Boggess JF, Bae-Jump VL. Rapamycin potentiates the effects of paclitaxel in endometrial cancer cells through inhibition of cell proliferation and induction of apoptosis. Int J Cancer 2010;126(5):1144-54 PubMed PMID: 19688827; PubMed Central PMCID: PMC2818608.
31. Zhou C, Gehrig PA, Whang YE, Boggess JF. Rapamycin inhibits telomerase activity by decreasing the hTERT mRNA level in endometrial cancer cells. Mol Cancer Ther 2003;2(8):789-95 PubMed PMID: 12939469.
32. Bieche I, Nogues C, Paradis V, Olivi M, Bedossa P, Lidereau R, et al. Quantitation of hTERT gene expression in sporadic breast tumors with a real-time reverse transcription-polymerase chain reaction assay. Clin Cancer Res 2000;6(2):452-9 PubMed PMID: 10690523. (Pubitemid 30111463)
33. Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984;22:27-55 PubMed PMID: 6382953.
34. Panvichian R, Orth K, Pilat MJ, Day ML, Day KC, Yee C, et al. Signaling network of paclitaxel-induced apoptosis in the LNCaP prostate cancer cell line. Urology 1999;54(4):746-52 PubMed PMID: 10510942. (Pubitemid 29449444)
35. Ling YH, Consoli U, Tornos C, Andreeff M, Perez-Soler R. Accumulation of cyclin B1, activation of cyclin B1-dependent kinase and induction of programmed cell death in human epidermoid carcinoma KB cells treated with taxol. Int J Cancer 1998;75(6):925-32 PubMed PMID: 9506539. (Pubitemid 28134119)
36. Rattan R, Giri S, Hartmann LC, Shridhar V. Metformin attenuates ovarian cancer cell growth in an AMP-kinase dispensable manner. J Cell Mol Med 2011;15(1): 166-78 PubMed PMID: 19874425.
37. Alimova IN, Liu B, Fan Z, Edgerton SM, Dillon T, Lind SE, et al. Metformin inhibits breast cancer cell growth, colony formation and induces cell cycle arrest in vitro. Cell Cycle 2009;8(6):909-15 PubMed PMID: 19221498.
38. Jefferies HB, Fumagalli S, Dennis PB, Reinhard C, Pearson RB, Thomas G. Rapamycin suppresses 5′TOP mRNA translation through inhibition of p70s6k. EMBO J 1997;16(12):3693-704 PubMed PMID: 9218810; PubMed Central PMCID: PMC1169993.
39. Bae-Jump VL, Zhou C, Boggess JF, Gehrig PA. Synergistic effect of rapamycin and cisplatin in endometrial cancer cells. Cancer 2009;115(17):3887-96 PubMed PMID: 19484784.
40. Iliopoulos D, Hirsch HA, Struhl K. Metformin decreases the dose of chemotherapy for prolonging tumor remission in mouse xenografts involving multiple cancer cell types. Cancer Res 2011;71(9):3196-201. PubMed PMID: 21415163.
41. Rocha GZ, Dias MM, Ropelle ER, Osorio-Costa F, Rossato FA, Vercesi AE, et al. Metformin Amplifies Chemotherapy-Induced AMPK Activation and Antitumoral Growth. Clin Cancer Res 2011;17(12):3993-4005. PubMed PMID: 21543517.
42. Asnaghi L, Calastretti A, Bevilacqua A, D'Agnano I, Gatti G, Canti G, et al. Bcl-2 phosphorylation and apoptosis activated by damaged microtubules require mTOR and are regulated by Akt. Oncogene 2004;23(34):5781-91 PubMed PMID: 15208671. (Pubitemid 39093023)
43. Stewart SA, Weinberg RA. Telomerase and human tumorigenesis. Semin Cancer Biol 2000;10(6):399-406 PubMed PMID: 11170862. (Pubitemid 32181910)
44. Yokoyama Y, Takahashi Y, Shinohara A, Lian Z, Tamaya T. Telomerase activity in the female reproductive tract and neoplasms. Gynecol Oncol 1998;68(2):145-9 PubMed PMID: 9514809. (Pubitemid 28150764)
45. Zheng PS, Iwasaka T, Yamasaki F, OuchidaM, YokoyamaM, Nakao Y, et al. Telomerase activity in gynecologic tumors. Gynecol Oncol 1997;64(1):171-5 PubMed PMID: 8995569. (Pubitemid 27026978)
46. Mo Y, Gan Y, Song S, Johnston J, Xiao X, Wientjes MG, et al. Simultaneous targeting of telomeres and telomerase as a cancer therapeutic approach. Cancer Res 2003;63(3):579-85 PubMed PMID: 12566299. (Pubitemid 36158134)
47. Multani AS, Li C, Ozen M, Imam AS, Wallace S, Pathak S. Cell-killing by paclitaxel in ametastaticmurinemelanoma cell line ismediated by extensive telomere erosion with no decrease in telomerase activity. Oncol Rep 1999;6(1):39-44 PubMed PMID: 9864398. (Pubitemid 128532795)
48. Le XF, Hittelman WN, Liu J, McWatters A, Li C, Mills GB, et al. Paclitaxel induces inactivation of p70 S6 kinase and phosphorylation of Thr421 and Ser424 viamultiple signaling pathways in mitosis. Oncogene 2003;22(4):484-97 PubMed PMID: 12555062. (Pubitemid 36188606)
49. Mutter GL, LinMC, Fitzgerald JT, KumJB, Baak JP, Lees JA, et al. Altered PTEN expression as a diagnostic marker for the earliest endometrial precancers. J Natl Cancer Inst 2000;92(11):924-30 PubMed PMID: 10841828.
50. An HJ, Lee YH, Cho NH, Shim JY, Kim JY, Lee C, et al. Alteration of PTEN expression in endometrial carcinoma is associated with down-regulation of cyclin-dependent kinase inhibitor, p27. Histopathology 2002;41(5):437-45 PubMed PMID: 12405911. (Pubitemid 35335004)
51. Terakawa N, Kanamori Y, Yoshida S. Loss of PTEN expression followed by Akt phosphorylation is a poor prognostic factor for patients with endometrial cancer. Endocr Relat Cancer 2003;10(2):203-8 PubMed PMID: 12790783. (Pubitemid 36758649)
52. Podsypanina K, Lee RT, Politis C, Hennessy I, Crane A, Puc J, et al. An inhibitor of mTOR reduces neoplasia and normalizes p70/S6 kinase activity in Pten+/-mice. Proc Natl Acad Sci U S A 2001;98(18):10320-5 PubMed PMID: 11504907. (Pubitemid 32803018)
53. Grunwald V, DeGraffenried L, Russel D, FriedrichsWE, Ray RB, HidalgoM. Inhibitors of mTOR reverse doxorubicin resistance conferred by PTEN status in prostate cancer cells. Cancer Res 2002;62(21):6141-5 PubMed PMID: 12414639. (Pubitemid 35244463)
54. Neshat MS, Mellinghoff IK, Tran C, Stiles B, Thomas G, Petersen R, et al. Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR. Proc Natl Acad Sci U S A 2001;98(18):10314-9 PubMed PMID: 11504908; PubMed Central PMCID: PMC56958.
55. Urick ME, Rudd ML, Godwin AK, Sgroi D, Merino M, Bell DW. PIK3R1 (p85{alpha}) is somatically mutated at high frequency in primary endometrial cancer. Cancer Res 2011;71(12):4061-7. PubMed PMID: 21478295.
56. Rudd ML, Price JC, Fogoros S, Godwin AK, Sgroi DC, Merino MJ, et al. A unique spectrum of somatic PIK3CA (p110alpha) mutations within primary endometrial carcinomas. Clin Cancer Res 2011;17(6):1331-40. PubMed PMID: 21266528.
57. Janku F, Tsimberidou AM, Garrido-Laguna I, Wang X, Luthra R, Hong DS, et al. PIK3CA mutations in patients with advanced cancers treated with PI3K/AKT/mTOR axis inhibitors. Mol Cancer Ther 2011;10(3):558-65. PubMed PMID: 21216929.
58. Steiner E, Plata K, Interthal C, Schmidt M, Faldum A, Hengstler JG, et al. Diabetes mellitus is a multivariate independent prognostic factor in endometrial carcinoma: a clinicopathologic study on 313 patients. Eur J Gynaecol Oncol 2007;28(2):95-7 PubMed PMID: 17479668. (Pubitemid 46697776)